Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2018

View Archived Issues

Study investigates IL-6 monoclonal antibody as a treatment for depression

Phase I data presented for T cells expressing an anti-CD19 CAR

ITTP demonstrates initial evidence of antitumoral activity in first-in-human trial

NovImmune presents data supporting approval of emapalumab for hemophagocytic lymphohistiocytosis

Phase IIb results for pimodivir alone or in combination with oseltamivir for seasonal influenza A

LncRNAs are gene trainers

Zinc plus its transporter kill resistant bacteria

Novel proteolysis-targeting chimeras degrading FLT3 and FAK

Fimepinostat may sensitize FLT3/ITD acute myeloid leukemia to gilteritinib

Metabolic strategy could tackle HIV reservoir, other infections

Carmot initiates phase I study of CT-868

Surface Oncology reduces scope of CD47 program SRF-231

Apexigen and with Columbia University Irving Medical Center collaborate on new phase II trial

Topline data presented from phase I studies of LX-2761

INmune Bio cleared to begin phase I study of INKmune in ovarian cancer

DWTI announces results of phase I/IIa study of H-1337

Novel anti-BMP6 targeted antibody reduces the need for EPO in anemia of chronic disease models

PASD1 found as immunotherapeutic target in colorectal cancer

FDA grants permission to initiate first-in-human study of ASN-008

Kalytera reports first cohort interim data from phase II trial of CBD in acute GvHD

Trial of TG-4001 with avelumab for HPV16-positive cancer advances into phase II

Bevespi Aerosphere approved in Europe for COPD

OSE-127 begins first-in-human trial for treatment of inflammatory autoimmune diseases

First patients enrolled in phase II SHIELD study of DAV-132

FDA clears Sirnaomics to begin phase II study of STP-705 for nonmelanoma skin cancer

Pfizer to discontinue STRIVE study of S. aureus vaccine due to futility

ARCHES study of Xtandi in metastatic hormone-sensitive prostate cancer meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...